Lifastuzumab vedotin [1401812-88-1]

TargetMol Chemicals

Lifastuzumab vedotin [1401812-88-1]

16

Research Use Only

Monoclonal

Lifastuzumab vedotin (DNIB0600A), an antibody-drug conjugate (ADC), consists of a humanized IgG1 monoclonal antibody targeting NaPi2b (MNIB2126A) linked to the potent antimitotic agent monomethyl auristatin E (MMAE), which disrupts cell division by inhibiting tubulin polymerization. This compound shows promise for research in non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) [1].

-20°C

12352203